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Abstract
Background: To improve the clinical outcome of patients who suffered ischemic stroke, cerebral ischemia-reperfusion
(I/R) injury is one of the major concerns that should be conquered. Inflammatory reactions are considered a major
contributor to brain injury following cerebral ischemia, and I/R exacerbates these reactions. The aim of this study was
to investigate the possible ameliorative effects of progranulin (PGRN) against I/R injury in mice.
Methods: In vivo I/R was induced in four-week-old male ddY mice by 2 h of MCAO (middle cerebral artery occlusion)
followed by 22 h of reperfusion. We evaluate expression of PGRN in I/R brain, efficacy of recombinant-PGRN (r-PGRN)
treatment and its therapeutic time-window on I/R injury. Two hours after MCAO, 1.0 ng of r-PRGN or PBS was
administered via intracerebroventricular. We assess neutrophil infiltration, expression of tumor necrosis factor (TNF)-α,
matrix metalloproteinase-9 (MMP-9) and phosphorylation of nuclear factor-κB (NF-κB) by immunofluorescense staining
and Western blotting. We also investigate neutrophil chemotaxis and intercellular adhesion molecule-1 (ICAM-1)
expression in vitro inflammation models using isolated neutrophils and endothelial cells.
Results: We found that expression of PGRN was decreased in the I/R mouse brain. r-PGRN treatment at 2 h after MCAO
resulted in a reduction in the infarct volume and decreased brain swelling; this led to an improvement in neurological
scores and to a reduction of mortality rate at 24 h and 7 d after MCAO, respectively. Immunohistochemistry, Western
blotting, and gelatin zymography also confirmed that r-PGRN treatment suppressed neutrophil recruitment into the I/R
brain, and this led to a reduction of NF-κB and MMP-9 activation. In the in vitro inflammation models, PGRN suppressed
both the neutrophil chemotaxis and ICAM-1 expression caused by TNF-α in endothelial cells.
Conclusions: PGRN exerted ameliorative effects against I/R-induced inflammation, and these effects may be due to the
inhibition of neutrophil recruitment into the I/R brain.
Keywords: Cerebral ischemia-reperfusion, Inflammation, Progranulin, Neuroprotection, Neutrophil recruitment
* Correspondence: hidehara@gifu-pu.ac.jp
1Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu
Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
Full list of author information is available at the end of the article
JOURNAL OF 
NEUROINFLAMMATION
© 2013 Egashira et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Egashira et al. Journal of Neuroinflammation 2013, 10:105
http://www.jneuroinflammation.com/content/10/1/105
Introduction
Stroke is a devastating disease and a leading cause of
death and severe disability worldwide [1]. Although the
majority of strokes are ischemic, few curative therapeutic
strategies are available for patients who have suffered an
ischemic stroke. At present, restoration of cerebral blood
flow is the best and, indeed, the only strategy available
to rescue the brain tissue from infarction, and tissue-
type plasminogen activator is, thus far, the only clinically
approved treatment for acute ischemic stroke. However,
if the time of reperfusion exceeds the therapeutic time
window, the risk of cerebral ischemia-reperfusion (I/R)
injury increases paradoxically. Severe I/R injury can
cause fatal hemorrhagic transformation or brain swell-
ing, which leads to poorer clinical outcomes.
Inflammatory reactions are considered a major con-
tributor to brain injury following cerebral ischemia [2].
It has been reported that cerebral ischemia triggers these
inflammatory reactions around the ischemic brain, and
that subsequent reperfusion exacerbates them [3]. Ex-
perimentally and clinically, proinflammatory mediators,
such as tumor necrosis factor (TNF)-α, are rapidly re-
leased from injured tissue in the acute phase of cerebral
ischemia [4,5]; this induces the recruitment and activa-
tion of inflammatory cells, including various types of
leukocytes [6,7]. This is one of the key features of the
neuroimmunological reaction to cerebral ischemia [2,8].
Among the various types of leukocytes, neutrophils are
the first to infiltrate into the ischemic brain, and they
peak one to three days following focal cerebral ischemia
[4,9]. During these early phases of post-cerebral I/R, infiltrat-
ing neutrophils cause critical pathological changes via sev-
eral mechanisms, including the release of elastase, excessive
production of reactive oxygen species (ROS), and induction
of matrix metalloproteinase-9 (MMP-9) [7,10,11]. Inhibition
of neutrophil infiltration, therefore, represents a potential
anti-inflammatory strategy for neuroprotection in the acute
stages of ischemic stroke [7].
Progranulin (PGRN) is a 593-amino acid, 68.5-kDa
cysteine-rich protein that is typically secreted in a highly
glycosylated 88-kDa form [12], and is known to perform
various biological functions, such as the regulation of
cell growth, embryonic development and tissue repair
[13,14]. Recently, it was reported that PGRN directly
binds to TNF receptors and suppresses TNF-α-mediated
inflammation in a mouse model of rheumatoid arthritis
[15]. In the central nervous system (CNS), PGRN has
been reported to function as a neurotrophic factor [16],
and decreased PGRN expression due to null mutations
of the PGRN gene is thought to be associated with
frontotemporal lobar dementia [12,17]. Although these
previous studies suggest the interactions between in-
flammatory pathogenesis in the CNS and the potential
role of PGRN, the anti-inflammatory actions and the
therapeutic prospects of PGRN in acute neuronal injury
have not been investigated well [18].
In the present study, we examined whether PGRN has
potential ameliorative effects against brain I/R injury, and
also investigated the underlying mechanisms, mainly focus-
ing on the anti-inflammatory actions of PGRN by using an
experimental model of focal cerebral ischemia-reperfusion.
Materials and methods
Animals
All animal protocols were conducted in accordance with
the “Animal Research: Reporting In Vivo Experiments”
(ARRIVE) guidelines and approved by the animal experi-
ment committees of Gifu Pharmaceutical University and
Asahi University. All in vivo experimental procedures
were performed using male ddY mice (four weeks old;
body weight, 22 to 28 g; Japan SLC Ltd., Shizuoka,
Japan), unless otherwise stated. Animals were housed at
24°C ± 2°C under a 12-h light–dark cycle. Food and
water were available to all animals ad libitum.
Focal cerebral ischemia-reperfusion in mice
Mice were anesthetized using 2.0 to 3.0% isoflurane, and
maintained using 1.0 to 1.5% isoflurane in 70% N2O/
30% O2, delivered via a facemask with an animal general
anesthesia machine (Soft Lander, Sin-ei Industry Co.,
Ltd., Saitama, Japan). A midline skin incision was made
in order to expose the left common carotid artery. The
proximal portion of the common and external carotid
arteries were ligated; thereafter, an 8–0 nylon monofila-
ment (Ethicon, Somerville, NJ, USA), coated with a mix-
ture of silicone resin (Provil novo, Heraeus Kulzer
GmbH, Hanau, Germany), was introduced into the left
internal carotid artery through the arteriotomy of the
common carotid artery in order to obstruct the origin of
the middle cerebral artery (MCA) [19,20]. After occlu-
sion for 2 h, the nylon monofilament was gently with-
drawn to restore blood flow in the MCA region. In each
mouse, regional cerebral blood flow (rCBF) was moni-
tored by laser Doppler flowmetry (Omegaflow flo-N1;
Omegawave, Inc., Tokyo, Japan). Mice which did not
demonstrate a significant reduction (to less than 40%
baseline rCBF values) during middle cerebral artery oc-
clusion (MCAO) were excluded. Sham control mice
underwent the same surgical procedure, without ob-
struction of MCA. Body temperature of all animals was
maintained at 37.0 to 37.5°C with the aid of a heating
pad and heating lamp throughout these procedures.
After the surgery, mice were housed under the preopera-
tive conditions until further experimentation.
Recombinant PGRN treatment
First, for dose–response studies, mice were randomly di-
vided into four groups (n = 6 to 8 for each group). Two
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hours after the MCAO procedures, a Hamilton syringe
was used to give each mouse a single intracerebroven-
tricular (i.c.v.) injection, as has been described previously
[21], containing 0.1, 0.3 or 1.0 ng of recombinant PGRN
(r-PGRN; Recombinant Mouse Progranulin; R&D Systems,
Inc., Minneapolis, MN, USA) in 2 μl of phosphatase-
buffered saline (PBS); vehicle-treated control mice were
injected with the same volume of PBS.
To investigate the long-term efficacy of r-PGRN treatment,
mice were randomly divided into 1.0 ng r-PGRN-treated
and vehicle-treated groups (n = 9 or n = 10 for each group).
Their survival rates following MCAO were evaluated over a
seven-day follow-up period.
For therapeutic time-window studies, mice were admin-
istered 1.0 ng of r-PGRN diluted in 2 μl PBS via i.c.v. ad-
ministration 6 h after MCAO, while vehicle-treated
control mice were injected with the same volume of
PBS (n = 8 or n = 9 for each group).
For immunofluorescence staining and Western blot
analysis of I/R tissue, mice were administered 1.0 ng of
r-PGRN diluted in 2 μl PBS via i.c.v. administration 2 h
after MCAO, while vehicle-treated control mice were
injected with the same volume of PBS at the same time
point (n = 4 or n = 5 for each group).
Measurement of infarct and cerebral edema volumes
Mice were euthanized 24 h after the induction of focal
cerebral ischemia. Their forebrains were quickly re-
moved and sectioned coronally into five serial 2-mm
slices. Tissue slices were placed in a 2% solution of 2, 3,
5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich, St.
Louis, MO, USA) at 37°C for 20 minutes, and then fixed
in 10% buffered formalin. Digital images of the caudal
aspect of each slice were obtained using a digital camera
(Coolpix 4500, Nikon, Tokyo, Japan). The infarct, ipsilat-
eral hemisphere and contralateral hemisphere areas were
all measured using image-processing software (Image-J
version 1.43 h; National Institutes of Health, Bethesda,
MD, USA), and infarct volume was calculated as has
been previously reported [19]. Cerebral edema was also
calculated using the following formula: (infarct volume +
ipsilateral undamaged volume – contralateral volume) ×
100/contralateral volume (%) [20].
Neurological deficit scoring
Mice were tested for neurological deficits 24 h after
MCAO, and scored as described previously [19]. The
possible scores were as follows: 0, no observable neuro-
logical deficits (normal); 1, failure to extend the right
forepaw (mild); 2, circling to the contralateral side (mod-
erate); and 3, loss of walking or righting reflex (severe).
The investigator who rated the mice was blinded to their
initial treatment condition.
Immunofluorescence staining and cell counting in brain
sections
Mice were anesthetized with an intraperitoneal injection
of sodium pentobarbital (50 mg/kg, i.p.) 24 h after the
induction of focal cerebral ischemia (n = 4 for each
group), and perfused transcardially with 4% paraformal-
dehyde (PFA). The forebrain was removed, fixed in 4%
PFA for 24 h and frozen. Fresh frozen forebrains were
sliced into 12-μm-thick coronal sections by using a cryo-
stat vibratome (Leica CM 1850; Leica Microsystems,
Buffalo Grove, IL, USA), and sectioned tissues were
placed onto individual slides. To identify infiltrating neu-
trophils on I/R brain slices, we performed immunohisto-
chemistry for myeloperoxidase (MPO). Slides were blocked
with 1% normal horse serum (Sigma-Aldrich) in PBS for 1
h at room temperature, and then incubated with the pri-
mary antibody for MPO (1:100; Abcam, Eugene, OR, USA)
overnight at 4°C. The next day, slides were washed three
times with PBS for 10 minutes each time, and then incu-
bated with the secondary antibody Alexa Fluor 546 donkey
anti-rabbit IgG (1:500; Molecular Probes, Eugene, OR,
USA), for 1 h at room temperature. After three washes
with PBS, the slides were incubated in Hoechst 33342
(1:10,000; Molecular Probes) for 10 minutes to provide nu-
clear counterstaining. Finally, slides were mounted using
Vectashield fluorescent mounting medium (Vector La-
boratory, Burlingame, CA, USA) and cover-slipped for mi-
croscopy. For quantitative analysis of cell number in the
infarcted cortex and the corresponding region in sham ani-
mals, the slides were visualized and digitally photographed
using a confocal microscope at a ×40 magnification
(Fluoview FV-10; Olympus, Tokyo, Japan). Three fields of
view were randomly chosen and photographed to count
the number of MPO-positive cells in each section, and
Image-J was used to analyze each picture. All analysis was
performed blinded to the treatment condition.
Western blot analysis
Expression levels of PGRN or MMP-9, and phosphoryl-
ation of nuclear factor-κB (NF-κB) in I/R brain were
evaluated by Western blot analysis. I/R or sham control
brain tissues (n = 4 or n = 5 for each group) were col-
lected, and the brains were cut into 2-mm-thick coronal
sections 6 to 8 mm from the frontal pole, and carefully
separated into ipsilateral and contralateral hemispheres,
with respect to the infarct location. The collected ipsilat-
eral brain tissues were homogenized in lysis buffer (50
mM Tris–HCl (pH 8.0), containing 100 mM NaCl, 50
mM EDTA, 1% Triton X-100, and protease inhibitor
cocktail (Sigma-Aldrich)) to extract the protein. Samples
were centrifuged at 12,000 × g for 30 minutes at 4°C,
and the supernatant collected. Equivalent amounts of
total protein were separated by their molecular weights
on SDS-PAGE gradient gel (SuperSep Ace; Wako Pure
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Chemicals, Osaka, Japan), and transferred to polyvinylidene
difluoride (PVDF) membranes (Immobilon-P; Millipore
Corporation, Billerica, MA, USA). Transfer was followed
by blocking with 5% skimmed milk in TBS with 0.05%
Tween-20 solution (TBS-T) for 30 minutes. Membranes
were incubated overnight with primary antibodies at 4°C
as follows: rat anti-PGRN (1:1,000, R&D Systems, Inc.),
rabbit anti-MMP-9 (1:1,000, Millipore Corporation), rabbit
anti-phosphorylated NF-κB (1:1,000, Cell Signaling Tech-
nology, Danvers, MA, USA), rabbit anti-total NF-κB
(1:1,000, Cell Signaling Technology), and mouse anti-β
-actin (1:5,000; Sigma-Aldrich). After three washes with
TBS-T, membranes were incubated with the appropriate
horseradish peroxidase-conjugated secondary antibodies
(Thermo Fisher Scientific, Waltham, MA, USA) for 1 h at
room temperature. After the final wash with TBS-T, immu-
noreactive bands were detected using a Lumino Imaging
Analyzer (LAS-4000; Toyobo Engineering, Osaka, Japan).
Signal intensity was measured using Image-J software, and
normalized to the β-actin signal intensity.
Gelatin zymography
MMP-9 activation was analyzed by gelatin zymography
using a gelatin zymography kit (Cosmo Bio, Tokyo,
Japan). I/R or sham control brain tissues (n = 3 for sham
or n = 4 for each treated group) were collected, and tis-
sue samples were lysated, homogenized and protein con-
centration was measured with Western blotting. Twenty
micrograms of total proteins were subjected to electro-
phoresis in polyacrylamide gels containing 0.5 mg/mL
gelatin in the presence of SDS under non-reducing con-
ditions, washed twice in 2.5% Triton X-100 for 1 hour,
rinsed briefly, and incubated at 37°C for 48 hours in 100
mmol/L Tris–HCl (pH 7.4) and 10 mmol/L CaCl2. Then
they were stained with Coomassie Brilliant Blue R-250
and destained in a solution of 7.5% acetic acid and 5%
methanol. Zones of enzymatic activity appeared as clear
bands against a blue background; their signal intensity
was measured using Image-J software.
Neutrophil isolation and assay for binding of 125I-labeled
TNF-α to the neutrophil surface
Male Wistar rats weighing 250 to 300 g (Japan SLC,
Ltd.) were used for neutrophil isolation experiments.
The animals were intraperitoneally injected with 25 to
30 mL of a 6.0% colloidal suspension of casein. Eighteen
hours later, the animals were euthanized, and peritoneal
exudates were collected from the peritoneal cavities. The
samples were then centrifuged at 800 × g for 10 minutes
at 4°C, and the resulting pellet was suspended in 5 mL
of ice-cold hypotonic buffer (0.15 M NH4Cl, 1 mM
KHCO3, 1 mM EDTA) and placed on ice for 10 s in
order to remove contaminating erythrocytes. The neu-
trophils were then pelleted by centrifugation (800 × g for
10 minutes) and washed twice with 5 mL of PBS. This
fraction, which contained over 95% viable neutrophils,
was used for the following experiment [22]. 125Iodine-
labeled recombinant human TNF-α was purchased
from PerkinElmer, Inc. (Boston, MA, USA; specific ac-
tivity 2.8 Bq/pg). Isolated neutrophils were seeded in
six-well plates at a density of 1 × 105 cells/well, and
cultured for 1 h at room temperature with a constant
amount of 125I-TNF-α (50 pg/mL) and different amounts
of r-PGRN (between 0 and 250 ng/mL; R&D Systems,
Inc.). For determination of nonspecific binding, cells were
also incubated with 125I-TNF-α in the presence of a 500-
fold excess of unlabeled TNF-α (Recombinant Human
TNF-α; R&D Systems, Inc.). After incubation, cells
were washed three times with cold PBS. The cells were
subjected to a gamma scintillation counter. Specific
binding was calculated by subtracting the nonspecific
binding from the total binding. Data were obtained
from three independent experiments.
Neutrophil chemotaxis assay
Screening for neutrophil chemotaxis was performed using
an EZ-TAXIScan chemotaxis apparatus (Effector Cell In-
stitute, Kawasaki, Japan), as has been previously described
[22]. Briefly, neutrophils were stimulated by the addition
TNF-α (100 ng/ mL; Recombinant Mouse TNF-α; R&D
Systems, Inc.) and different amounts of r-PGRN (between
0 and 250 ng/mL; R&D Systems, Inc.) to one hole,
while treated cells were placed in a contra-hole of the
microchannel. Migration of neutrophils toward the
high concentration of each sample was recorded using
a charge-coupled device (CCD) camera, with time-lapse
images captured every 60 s for 60 minutes at 25°C
with the EZ-TAXIScan apparatus. Sequential files and
superimposed images of chemotaxing cells were processed
using Motic Image Plus software (Shimadzu Corp., Kyoto,
Japan). Viable cells were assessed in terms of their migra-
tion speed, straightness and directionality of cell move-
ment, as previously described [23].
Human microvascular endothelial cell culture and
treatment
Human brain microvascular endothelial cells (hBMVEC)
were purchased from Cell Systems (Kirkland, WA, USA).
They were seeded at a density of 1 × 105 cells per well
onto 12-well culture plates, and incubated in EBM-2
medium with endothelial growth supplements (Lonza,
Walkersville, MD, USA) at 37°C in 5% CO2 until they
reached 70% confluence. To investigate the effects of
PGRN on the TNF-α induced inflammation model, the
culture medium was removed, and cells were washed
twice with PBS, before they were treated with varying con-
centrations of recombinant human PGRN (rh-PGRN; Re-
combinant Human Progranulin; R&D Systems, Inc.), and
Egashira et al. Journal of Neuroinflammation 2013, 10:105 Page 4 of 13
http://www.jneuroinflammation.com/content/10/1/105
10 ng/mL of TNF-α (Recombinant Human TNF-α; R&D
Systems, Inc.) for 20 h, in accordance with the methods
described previously [24]. Following these treatments, cell
lysates were collected, and Western blot analysis was
performed in order to assess the expression levels of inter-
cellular adhesion molecule-1 (ICAM-1), using the proto-
col described above, and the primary antibodies of rabbit
anti-ICAM-1 (1:1,000; Cell Signaling Technology) and
mouse anti-β-actin (1:5,000; Sigma-Aldrich).
Statistical analysis
All values are expressed as mean ± SEM. The quantita-
tive variables were statistically analyzed using Student’s
two-tailed t-test for two-group comparisons, and a one-
way ANOVA followed by Dunnett’s test for multiple
pair-wise comparisons. A Wilcoxon signed-rank test was
used for the repeated assessment of neurological scores,
and a Log-rank test was used for the assessment of sur-
vival rates during follow-up periods. P-values of less than
0.05 were considered statistically significant. All statisti-
cal analyses were performed using JMP 7 for Macintosh
(SAS Institute Inc., Cary, NC, USA).
Results
Expression of PGRN in the ischemia-reperfusion brain
First, we examined the expression levels of PGRN in I/R
brain at 24 h after the induction of focal cerebral ische-
mia. Interestingly, we found that PGRN expression was
significantly decreased in I/R brain tissue. In the I/R
brain, a 60% decrease in PGRN expression was ob-
served compared to the sham contralateral, non-
ischemic brain, 24 h after MCAO (Figure 1A,B; P <0.01
vs. sham contralateral brain; one-way ANOVA followed
by Dunnett’s test).
Efficacy of r-PGRN treatment on focal cerebral ischemia-
reperfusion injury
Next, we examined whether the administration of r-PGRN
would reduce infarct volume. The treatment protocol for
this experiment is shown in Figure 2A. Mice developed an
infraction affecting the left hemisphere after 2 h of MCAO,
followed by 22 h of reperfusion; no mice, in any experi-
mental group, died during this experiment. The adminis-
tration of 1.0 ng of r-PGRN led to a 57% reduction in
infarct volume (Figure 2B, 2C; P <0.01; one-way ANOVA
followed by Dunnett’s test), and a 77% reduction in brain
swelling, compared to the vehicle-treated group (Figure 2D;
P <0.01; one-way ANOVA followed by Dunnett’s test). In
the groups treated with 0.1 and 0.3 ng r-PGRN, we ob-
served an 18% and 25% reduction in infarct volume, and a
26% and 40% reduction in brain swelling, respectively.
However, there was no statistically significant difference
between these groups and the vehicle-treated group. The
neurological scores of each treated group 24 h after
MCAO are shown in Figure 2E. Only the group treated
with 1.0 ng r-PGRN had significantly better neurological
function at 24 h after MCAO than at 2 h after MCAO
(P <0.05; Wilcoxon signed-rank test). Figure 2F shows
the survival rates of both the 1.0 ng r-PGRN-treated
and vehicle-treated groups. The 1.0 ng r-PGRN-treated
group had a high survival rate throughout the follow-
up period (100% on Days 1 to 3; 90% on Days 4 to 7);
in contrast, the vehicle-treated group showed a con-
tinuous reduction of survival rate from Day 2 (88.9%)
until Day 7 (44.4%). There was a statistically significant
difference between the two groups (P <0.05; Log-rank
test).
Therapeutic time-window for r-PGRN treatment
We also investigated the therapeutic time-window for
r-PGRN treatment (the experimental protocol is shown
in Figure 3A). Delayed administration of 1.0 ng of r-PGRN
6 h after MCAO did not reduce the infarct volume
(Figure 2B); it did, however, lead to a 56% reduction of
brain swelling compared to those of the vehicle-treated
group (Figure 2C; P <0.05; Student’s t-test).
Figure 1 Expression of progranulin in the ischemia-reperfusion
injured brain. Progranulin (PGRN) expression was significantly
decreased following ischemia-reperfusion (I/R) insults. (A)
Representative PGRN bands from the Western blotting analysis of
brain tissue taken from sham-operated and I/R animals; ipsilateral
and contralateral hemispheres to the middle cerebral artery
occlusion (MCAO). (B) Optical densitometry quantification of PGRN
protein levels, normalized to β-actin. In the I/R brain, the expression
of PGRN was significantly decreased 24 h after the induction of
transient cerebral ischemia. **P <0.01 vs. sham contralateral brain;
one-way ANOVA followed by Dunnett's test; n = 4 for each group.
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r-PGRN attenuates neutrophil infiltration into I/R brain
It has been reported that neutrophils are the first
leukocyte subpopulation to be recruited to the ischemic
brain, and an extensive infiltration of neutrophils was
observed 24 h after transient filament MCAO in mice
[25]. We examined whether r-PGRN treatment inhibits
neutrophil infiltration into the I/R brain. To identify in-
filtrating neutrophils, we stained the tissue for MPO. At
24 h after the induction of transient MCAO, the number
of MPO-positive cells was found to be significantly in-
creased in the vehicle-treated group (P <0.001 vs. sham op-
eration control; Student’s t-test). Notably, the number of
Figure 2 r-PGRN treatment reduces cerebral infarct volume and brain edema in transient focal cerebral ischemia. (A) Protocol for
surgery and r-PGRN administration. Intracerebroventricular (i.c.v.) injections of either vehicle or r-PGRN (0.1 to 1.0 ng) were administered 2 h after
middle cerebral artery occlusion (MCAO). All assessments, with the exception of survival rate evaluation, were performed at 24 h after the
induction of 2 h of transient MCAO. (B) Representative photograph showing TTC staining of coronal brain sections 24 h after MCAO in each
treatment group. (C) Administration of 1 ng of r-PGRN significantly reduced the infarct volume, (D) and reduced brain edema, compared to the
vehicle treatment. Although the 0.1 ng r-PGRN- and 0.3 ng r-PGRN-treated groups tended to experience reduced infarct volume and brain
edema, the difference was not statistically significant. * P <0.05 vs. vehicle-treated group; one-way ANOVA followed by Dunnett's test; n = 6 to
n = 8 for each group. (E) Only the 1.0 ng r-PGRN-treated group had significantly better neurological function at 24 h after MCAO than at 2 h
after MCAO. # P <0.05; Wilcoxon signed-rank test. (F) A higher survival rate was observed throughout the follow-up period in the 1.0 ng
r-PGRN-treated group. In contrast, a continuous reduction of the survival rate was observed in the vehicle-treated group. The difference
between the groups was statistically significant. † P <0.05; Log-rank test; n = 9 or n =10 for each group. r-PGRN, recombinant-progranulin.
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MPO-positive cells was significantly lower in the r-PGRN-
treatment group than in the vehicle-treated group (P <0.01;
Student’s t-test) (Figure 4A,B).
PGRN acts as an antagonist to TNF-α and suppresses
neutrophil chemotaxis
First, the saturation curve for specific 125I-TNF-α binding
to neutrophil surfaces was determined (Figure 5A); in ac-
cordance with these results, 50 pg/mL of 125I-TNF-α was
used in the following experiments. 125I-TNF-α binding
significantly decreased with increasing concentrations of
PGRN, from 100 to 250 ng/mL (Figure 5B; P <0.001;
one-way ANOVA followed by Dunnett’s test). These
results strongly indicate that PGRN inhibits TNF-α/TNF-
receptor interactions. Next, we investigated whether TNF-
α causes neutrophil chemotaxis, and, if it does, whether
PGRN suppresses the TNF-α-induced neutrophil chemo-
taxis. In these experiments, we found that neutrophil
chemotaxis was indeed induced by TNF-α, and that
PGRN significantly suppressed this chemotaxis in a
concentration-dependent manner; doses of 100 and 250
ng/mL of PGRN significantly suppressed both neutrophil
migration speed (Figure 5C; P <0.01, and P <0.001 vs.
TNF-α only group, respectively; one-way ANOVA
followed by Dunnett’s test) and the straightness of migra-
tion courses (Figure 5D; P <0.001 vs. TNF-α only group,
for each dose; one-way ANOVA followed by Dunnett’s
test). However, the directionality of migration was not sig-
nificantly affected (Figure 5E).
PGRN treatment reduces the expression of ICAM-1 in
TNF-α-treated hBMVECs
Proinflammatory cytokines induced by I/R facilitate the
infiltration of leukocytes into brain tissue by activating
and inducting adhesion molecules on vascular endothe-
lial cells. In particular, intracellular adhesion molecule-1
(ICAM-1) plays an important role in the firm adherence
of leukocytes [26]. In the present study, hBMVECs
treated with TNF-α were used as an in vitro inflamma-
tory model of brain endothelial cells. After 20 h of ex-
posure to 10 ng/mL of TNF-α, ICAM-1 expression in
the hBMVECs was significantly increased (P <0.001 vs.
control group; Student’s t-test). This increased ICAM-1
expression was significantly attenuated by both 100 and
250 ng/mL of rh-PGRN, in a concentration-dependent
manner (P <0.05 and P <0.01 vs. vehicle-treated group,
respectively; one-way ANOVA followed by Dunnett’s
test) (Figure 6A,B).
Effects of r-PGRN on the phosphorylation of NF-κB, and
expression, activation of MMP-9 in the I/R brain
The effects of r-PGRN treatment on the phosphorylation
of NF-κB, and on the expression and the activation of
MMP-9 24 h after the induction of transient focal
Figure 3 The effects of delayed administration of r-PGRN 6 h after transient MCAO. (A) Protocol for surgery and PGRN administration.
Injections (i.c.v.) of either vehicle or r-PGRN (1.0 ng) were administered 6 h after the MCAO procedure. All assessments were performed at 24 h
after the induction of 2 h of transient MCAO. (B) Administration of 1 ng of r-PGRN 6 h after MCAO did not reduce the infarct volume assessed at
24 h after the induction of 2 h of MCAO; (C) however, it significantly reduced brain edema. N.S. not significant; * P <0.05 vs. vehicle-treated
group; Student's t-test; n = 8 or n = 9 for each group. i.c.v., intracerebroventricular; MCAO, middle cerebral artery occlusion; PGRN, progranulin;
r-PGRN, recombinant-progranulin.
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ischemia are shown in Figure 6. In the I/R brain, the
level of phosphorylated NF-κB was significantly in-
creased in the vehicle-treated group (P <0.01 vs. the
sham control group; Student’s t-test), while the level of
total NF-κB did not differ between the groups. This in-
creased level of NF-κB phosphorylation was significantly
suppressed by r-PGRN treatment (P <0.05 vs. vehicle-
treated group; Student’s t-test) (Figure 7A). The expres-
sion of MMP-9 was significantly increased in the
vehicle-treated group (P <0.05 vs. sham control group;
Student’s t-test), and this increase was suppressed by r-
PGRN treatment (P <0.05 vs. vehicle-treated group; Stu-
dent’s t-test) (Figure 7B). Additionally, activated MMP-9
detected by gelatin zymography was significantly
increased in the vehicle-treated group (P <0.001 vs.
sham control group; Student’s t-test), and this increase
was suppressed by r-PGRN treatment (P <0.05 vs.
vehicle-treated group; Student’s t-test) (Figure 7C).
Discussion
Many previous studies have indicated a role for PGRN
in the pathogenesis of chronic CNS disorders. In the
CNS, PGRN is expressed in both neurons and microglia
[27], and it is well recognized that a decreased level of
functional PGRN, due to null or missense mutations of the
PGRN gene, causes frontotemporal lobar degeneration,
with ubiquitin-positive inclusions [12,17,28]. PGRN is se-
creted as a glycosylated polypeptide, and is thought to
Figure 4 r-PGRN treatment significantly suppresses neutrophil recruitment into the I/R brain following MCAO. (A) Representative
immunohistochemical staining for myeloperoxidase (MPO) in each of the areas of interest in the sham-operation, vehicle-treated and r-PGRN
-treated groups. (B) Quantification of MPO-immunoreactive cells. The number of MPO-positive cells was significantly higher in the vehicle-treated
mice than in the r-PGRN-treated mice. Scale bar = 20 μm. ## P <0.01 vs. sham-operation mice; ** P <0.01 vs. vehicle-treated mice; Student's t-test.
n = 4 or n = 5 for each group. I/R, ischemia-reperfusion; MCAO, middle cerebral artery occlusion; r-PGRN, recombinant-progranulin.
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exert at least some of its biological functions within the
extracellular space; it is considered to play an important
role in neuronal tissue homeostasis [29]. However, the bio-
logical functions of PGRN in case of acute neuronal injury
remain unclear.
In this study, we found that the expression of PGRN
was significantly decreased in the I/R brain 24 h after the
induction of transient focal cerebral ischemia (Figure 1). It
is known that full-length PGRN acts as an anti-
inflammatory agent; however, its derivative, granulin, acts
in the opposite manner, stimulating the production of
proinflammatory cytokines [30]. During an inflammatory
reaction, neutrophils and macrophages secrete the prote-
ase elastase that digests full-length PGRN into individual
6-kDa granulin peptides, potentially exacerbating the in-
flammation [30]. It has been suggested that PGRN inhibits
the neutrophil activation and recruitment triggered by
proinflammatory mediators in the initial stages of inflam-
mation. However, as the level of proinflammatory media-
tors rise, neutrophil elastase (NE) levels, secreted by
activated neutrophils, increase and NE degrades PGRN
into granulin. Subsequently, neutrophils release further
proinflammatory mediators and chemotactic agents,
enhancing the recruitment of further neutrophils and
exacerbating inflammation [31]. We, therefore, hypoth-
esized that decreased levels of PGRN potentiates the
neuroinflammation induced by I/R, and that its mech-
anisms are, at least in part, due to promotion of neu-
trophil recruitment and activation.
In the present study, we demonstrated that the admin-
istration of r-PGRN significantly attenuated neuronal in-
jury following I/R, with a 6-h therapeutic time-window
(Figures 2 and 3). Recently, Tao et al. reported that
transgenic mice over-expressing PGRN had smaller cere-
bral infarctions and better functional outcomes after
focal cerebral ischemia than wild-type mice [18]. They
also showed that the expression of proinflammatory cy-
tokines was significantly lower in astrocytes cultured
from PGRN-over-expressing mice. However, they did
not fully elucidate the anti-inflammatory mechanisms of
Figure 5 PGRN inhibits 125I-TNF-α binding to neutrophil surfaces and suppresses neutrophil chemotaxis induced by TNF-α. (A)
Saturation curve for specific 125I-TNF-α binding to neutrophil surfaces was determined, and in accordance with these results, 50 pg/mL of 125I-
TNF-α was used in the subsequent experiments. (B) The 125I-TNF-α binding significantly decreased with increasing concentrations of PGRN. ***P
<0.001 vs. 0 ng/mL of PGRN group; one-way ANOVA followed by Dunnett's test. Data were obtained from three independent experiments and
presented as mean ± SEM. (C, D, E) Neutrophil chemotaxis was induced by TNF-α, and PGRN was found to significantly suppress this effect in a
concentration-dependent manner; at 100 and 250 ng/mL of PGRN attenuates the migration speed and straightness of the route of migration, but
did not affect the directionality of migration. ### P <0.001 vs. control group; Student t-test; ** P <0.01, *** P <0.001 vs. TNF-α only group; one-way
ANOVA followed by Dunnett's test; n = 5 for each group. PGRN, progranulin; TNF-α, tumor necrosis factor-alpha.
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PGRN. Experimentally and clinically, focal cerebral is-
chemia induces the recruitment and activation of inflam-
matory cells, including various types of leukocytes [6,7].
Among the various leukocytes, neutrophils are the first
to infiltrate into the ischemic brain, and neutrophil infil-
tration is recognized as an important pathogenic factor
following a cerebral ischemic insult [32]. Neutrophil
infiltration into the brain tissue was found to be more
prominent in transient, but not in permanent, ische-
mia in the early phase [25,33], and occurred within 30
minutes to a few hours, peaking within the first three
days [4,9]. In our study, consistent with the findings of
previous studies, a marked increase in neutrophil infil-
tration following I/R insult was observed in the infarct
cortex in the vehicle-treated group. r-PGRN treatment
significantly suppressed this neutrophil infiltration
(Figure 4), with these results suggesting that r-PGRN
treatment attenuates the neuronal damage caused by
I/R through the suppression of harmful neutrophil
recruitment.
In the earliest phase of cerebral ischemia, TNF-α is re-
leased predominantly from microglia [4,5,34], and plays
a critical role in subsequent I/R-induced injury. It has
been suggested that TNF-α primes neutrophil extravasa-
tion from blood vessels during inflammation [31]. More
recently, it was reported that PGRN binds directly to
TNF receptors and suppresses TNF-α-mediated inflam-
mation in a mouse model of rheumatoid arthritis [15].
To the best of our knowledge, we are the first to report
that PGRN directly inhibits TNF-α binding to neutro-
phils, and to confirm that PGRN significantly suppresses
the neutrophil chemotaxis triggered by TNF-α in a
concentration-dependent manner, as demonstrated by
an in vitro assay (Figure 5). These results suggest that
PGRN is a potentially useful candidate for the attenu-
ation of TNF-α-mediated inflammation.
TNF-α is considered to be a major mediator of inflam-
matory responses in vascular endothelial cells [24]. Cell-
adhesion molecules, particularly ICAM-1, are induced
during the early stages of ischemia by TNF-α, along with
other proinflammatory cytokines [35,36]; subsequently,
leukocytes begin to firmly adhere to endothelial cells,
from where they can infiltrate into the brain tissue
(Smith et al. 1998; Stanimirovic et al. 1997). To deter-
mine the effects of PGRN on endothelial inflammation,
we used hBMVECs, which we exposed to TNF-α, as an
in vitro model of endothelial inflammation, in accordance
with previous literature [24]. In this model, co-treatment
with PGRN significantly reduced TNF-α-induced ICAM-1
expression in a concentration-dependent manner (Figure 6).
These results indicate that PGRN has dual mechanisms of
suppressing neutrophil recruitment, one through the direct
inhibition of neutrophil chemotaxis, and the other, by
ameliorating endothelial inflammation. Additionally, in the
I/R brain, TNF-α may directly affect neuronal or glial cells
by binding TNF receptors and up-regulating inflammatory
signals. Previous studies have suggested that neurons
express both TNF-receptor1 (TNF-R1) and 2 (TNF-
R2) [37], and that TNF-R2 signaling plays a larger role
in inflammatory responses following stroke [5]. It was
reported that PGRN had higher binding affinity for
TNF-R1 and TNF-R2, especially TNF-R2, when com-
pared to TNF-α [15]. Taken together, these findings
suggest that PGRN potentially attenuates the neuronal in-
flammation caused by TNF-α. Although anti-inflammatory
approaches targeting neutrophils or ICAM-1 have proved to
be successful in animal models, attempts to transfer this
knowledge to a clinical setting have thus far been unsuccess-
ful [7]. In comparison with these approaches, PGRN treat-
ment seems to be more promising with regard to clinical
applications because of its multiple anti-inflammatory effects
on neutrophils, vascular endothelium and neuronal cells.
Figure 6 PGRN ameliorates TNF-α-induced inflammation in
hBMVECs. (A) Representative bands from the Western blotting
analysis of ICAM-1 and β-actin. (B) Optical densitometry
quantification of ICAM-1, normalized to β-actin. TNF-α (10 ng/mL)
induced an approximately eight-fold increase in ICAM-1 in hBMVECs
after a 20-h exposure. ### P <0.001 vs. control group; Student's t-
test. PGRN significantly suppressed TNF-α-induced ICAM-1
expression in a concentration-dependent manner. * P <0.05, ** P
<0.01 vs. vehicle-treated group; one-way ANOVA followed by
Dunnett's test; n = 4 for each group. hBMVECs, human brain
microvascular endothelial cells; ICAM-1, intercellular adhesion
molecule-1; PGRN, progranulin; TNF-α, tumor necrosis factor-alpha.
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Finally, we confirmed that r-PGRN treatment signifi-
cantly reduces the phosphorylation of NF-κB and the ex-
pression of MMP-9 in the I/R brain (Figure 7). Expression
and activation of MMP-9 following cerebral ischemia are
closely associated with disruption of the blood–brain
barrier (BBB), and cause severe brain edema or hemorrhagic
transformation [38]. Although post-ischemic MMP-9
expression was increased in neurons, glia, endothelial
cells and infiltrated neutrophils, recruited neutrophils
are considered the key cellular source of MMP-9,
which promotes further recruitment of neutrophils in
a positive feedback manner and causes BBB disruption
[39]. Hence, inhibition of neutrophil recruitment by
PGRN also suppresses MMP-9 expression by terminat-
ing the abovementioned positive feedback mechanism,
and thus ameliorates BBB disruption.
NF-κB is an oxidative stress-responsive transcription
factor, and its involvement in I/R injury is well recognized
[40]. In the early phase of post-cerebral I/R, infiltrating
neutrophils cause excessive production of ROS, resulting
in oxidative stress in the affected brain tissue. Oxidative
stress promotes the activation of NF-κB and its trans-
location to the nucleus, where activated NF-κB medi-
ates the transcription of various inflammatory genes,
thus inducing inflammation. In this study, we found a
significant reduction in phosphorylated NF-κB levels
in r-PGRN-treated mice. Because excessive amounts of
ROS are produced by recruited neutrophils in the I/R
brain [11], it is reasonable to speculate that the inhib-
ition of neutrophil recruitment by PGRN leads to the
suppression of NF-κB activation and ameliorates in-
flammation via the NF-κB pathway.
Conclusion
The potentially beneficial effects of PGRN in ischemic
stroke have been confirmed, using both in vivo and
in vitro experimental models of cerebral I/R injury. These
effects are, at least in part, due to anti-inflammatory
mechanisms and, specifically, the inhibition of neutrophil
infiltration. The current findings indicate the feasibility of
r-PGRN treatment as a novel anti-inflammatory therapy,
which may prove beneficial in the acute stage of ischemic
stroke.
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